

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/129560 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/30 (2006.01)
C07K 16/28 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/EP2021/086559

(22) International Filing Date:

17 December 2021 (17.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/127,224 18 December 2020 (18.12.2020) US
20306633.7 21 December 2020 (21.12.2020) EP

(71) Applicants: **ABLYNX NV** [BE/BE]; Technologiepark 21,
9052 Zwijnaarde (BE). **SANOFI** [FR/FR]; 54 rue La
Boétie, 75008 Paris (FR).

(72) Inventors: **JANSSEN, Daniel**; c/o Ablynx N.V., Patent
Department, Technologiepark 21, 9052 Zwijnaarde (BE).
BOUTTON, Carlo; c/o Ablynx N.V., Patent Depart-
ment, Technologiepark 2, 9052 Zwijnaarde (BE). **DOM-
BRECHT, Evelyne**; c/o Ablynx N.V., Patent Department,
Technologiepark 21, 9052 Zwijnaarde (BE). **LAUKENS,
Bram**; c/o Ablynx N.V., Patent Department, Technolo-
giepark 21, 9052 Zwijnaarde (BE). **MEONI, Paolo**; c/
o Ablynx N.V., Patent Department, Technologiepark 21,
9052 Zwijnaarde (BE). **PAO, Lily**; c/o Sanofi, 55 Corpo-
rate Drive, Bridgewater, New Jersey 08807 (US). **PYPE,
Jan**; c/o Ablynx N.V., Patent Department, Technologiepark
21, 9052 Zwijnaarde (BE). **SCHOTTE, Peter**; c/o Ablynx
N.V., Patent Department, Technologiepark 21, 9052 Zwi-
jnaarde (BE). **SERRUYS, Benedikte**; c/o Ablynx N.V.,
Patent Department, Technologiepark 21, 9052 Zwijnaarde
(BE). **VINTEM, Ana Paula**; c/o Ablynx N.V., Patent
Department, Technologiepark 21, 9052 Zwijnaarde (BE).
VAN HOORICK, Diane; c/o Ablynx N.V., Patent Depart-
ment, Technologiepark 21, 9052 Zwijnaarde (BE).

(74) Agent: **HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB, ASSOCIATION
NO. 151**; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING GLYPICAN-3
AND T CELL RECEPTOR

(57) Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.



WO 2022/129560 A1